IVAX (IVX) Inactive 10-Q2003 Q1 Quarterly report

Filed: 15 May 03, 12:00am

Content analysis

Positive
Negative
Uncertain
Constraining
Legalese
Litigious
Readability	H.S. freshman Avg

New words: absolute, Additionally, Alcon, allegedly, andTurner, API, applied, Aqueduct, assessed, assessment, billion, Boston, breach, Bulletin, caption, chain, chargeback, Chemo, ChemSource, circumvented, civil, collusion, complementing, comply, complying, conceived, conduct, Consent, conspiring, control, created, declaratory, defense, defraud, defrauding, degree, detected, deteriorate, district, environmental, EPA, equitable, ERISA, error, Europe, expend, failed, failing, faulty, federal, fee, forma, GenPharm, geographic, Good, highly, Iberica, implementation, inadequate, indemnity, individual, ingredient, inherent, interpretation, interpreted, intrinsic, Isaac, jointly, judgment, Kaye, King, law, likelihood, maximum, minimum, mistake, mix, model, negligence, nonrefundable, Northern, objective, override, Paul, penalty, people, permissible, pharmacy, plaintiff, PRASA, preliminary, pretreatment, prevent, pro, prospective, purportedly, quality, Quimica, recovery, region, reimburse, removing, repayment, resource, satisfied, schedule, secured, security, Sewer, shortly, simple, Sintetica, specific, specifically, stipulated, styledUnited, succeed, suit, suspended, system, theJohn, thirty, Thompson, treble, unknown, variable, violation, visual, volatility, weighted

Removed: AB, accumulated, achieved, ADS, aerosol, albuterol, amortized, anniversary, asthma, authorization, bearing, beclomethasone, Belgium, book, carried, case, Characterization, Chilean, Code, comprising, converting, covering, CVA, de, Delivery, Depositary, diagnostic, dipropionate, disposal, EITF, entered, exclusive, expanded, expired, extended, extraordinary, Florida, flunisolide, France, French, Fustery, generic, Geneva, Goldline, half, hemihydrate, HFA, Holding, impairment, indefinite, Indiana, indirectly, inhaler, initial, International, investment, Ireland, Issue, July, Laboratorio, life, Locasyn, Lokilan, longer, Louisiana, low, Maancirkel, Merck, merged, merger, Mexican, Morcob, Nasalide, negatively, Netpharma, newly, nondeductible, occurred, October, organization, organized, page, parent, partial, physical, pretax, program, Protein, public, put, reader, reporting, Reseller, reversed, Rhinalar, Scandinavia, settle, settled, similar, statutory, strike, substantially, Swedish, Syntex, tangible, technical, tender, test, tested, transaction, treat, treated, unfavorable, Vendor, Waterford, wholesale, workforce, Zenith

Search this filing

Filing tables

Export all tables to Excel

Filing exhibits

IVX similar filings

Filing view

Default size S M L
Default font Times Arial

External links

Share this filing

EXHIBIT 99.2

CERTIFICATION PURSUANT TO 18 U.S.C. SECTION 1350,

AS ADOPTED PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

In connection with the Quarterly Report of IVAX Corporation (the “Company”) on Form 10-Q for the period ending March 31, 2003, (the “Report”), as filed with the Securities and Exchange Commission on the date hereof, I, Thomas E. Beier, Senior Vice President – Finance and Chief Financial Officer, certify pursuant to 18 U.S.C. §1350, as adopted pursuant to §906 of the Sarbanes-Oxley Act of 2002, that:

The Report fully complies with the requirements of section 13(a) or 15(d) of the Securities Exchange Act of 1934, as amended; and

The information contained in the Report fairly presents in all material respects, the financial condition and results of operations of the Company.

/s/ THOMAS E. BEIER

Thomas E. Beier

Senior Vice President – Finance and

Chief Financial Officer

May 14, 2003